Zydus Cadila has received the final approval from the USFDA to market Glyburide Tablets USP in strengths of 1.25, 2.5 and 5 mg. Glyburide, which is an anti-diabetic drug will be produced at the group's formulations manufacturing facility at Baddi. The group now has more than 100 approvals and has so far filed over 280 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.
